PMID- 26036334
OWN - NLM
STAT- MEDLINE
DCOM- 20160325
LR  - 20220409
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 17
IP  - 1
DP  - 2015 Jun 3
TI  - Approaches for estimating minimal clinically important differences in systemic 
      lupus erythematosus.
PG  - 143
LID - 10.1186/s13075-015-0658-6 [doi]
LID - 143
AB  - A minimal clinically important difference (MCID) is an important concept used to 
      determine whether a medical intervention improves perceived outcomes in patients. 
      Prior to the introduction of the concept in 1989, studies focused primarily on 
      statistical significance. As most recent clinical trials in systemic lupus 
      erythematosus (SLE) have failed to show significant effects, determining a 
      clinically relevant threshold for outcome scores (that is, the MCID) of existing 
      instruments may be critical for conducting and interpreting meaningful clinical 
      trials as well as for facilitating the establishment of treatment recommendations 
      for patients. To that effect, methods to determine the MCID can be divided into 
      two well-defined categories: distribution-based and anchor-based approaches. 
      Distribution-based approaches are based on statistical characteristics of the 
      obtained samples. There are various methods within the distribution-based 
      approach, including the standard error of measurement, the standard deviation, 
      the effect size, the minimal detectable change, the reliable change index, and 
      the standardized response mean. Anchor-based approaches compare the change in a 
      patient-reported outcome to a second, external measure of change (that is, one 
      that is more clearly understood, such as a global assessment), which serves as 
      the anchor. Finally, the Delphi technique can be applied as an adjunct to 
      defining a clinically important difference. Despite an abundance of methods 
      reported in the literature, little work in MCID estimation has been done in the 
      context of SLE. As the MCID can help determine the effect of a given therapy on a 
      patient and add meaning to statistical inferences made in clinical research, we 
      believe there ought to be renewed focus on this area. Here, we provide an update 
      on the use of MCIDs in clinical research, review some of the work done in this 
      area in SLE, and propose an agenda for future research.
FAU - Rai, Sharan K
AU  - Rai SK
AD  - Arthritis Research Canada, 5591 No. 3 Road, Richmond, BC, V6X 2C7, Canada.
AD  - Department of Experimental Medicine, University of British Columbia, Vancouver 
      General Hospital, 10226-2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada.
FAU - Yazdany, Jinoos
AU  - Yazdany J
AD  - Department of Medicine, University of California, 1001 Potrero Ave, San 
      Francisco, CA, 94143, USA.
FAU - Fortin, Paul R
AU  - Fortin PR
AD  - Centre de recherche du CHU de Quebec, Division de Rhumatologie, Departement de 
      Medecine, Universite Laval, 2705 boulevard Laurier, Quebec, QC, G1V 2L9, Canada.
FAU - Avina-Zubieta, J Antonio
AU  - Avina-Zubieta JA
AD  - Arthritis Research Canada, 5591 No. 3 Road, Richmond, BC, V6X 2C7, Canada. 
      azubieta@arthritisresearch.ca.
AD  - Division of Rheumatology, Department of Medicine, University of British Columbia, 
      Suite 802 - 1200 Burrard Street, Vancouver, BC, V6Z 2C7, Canada. 
      azubieta@arthritisresearch.ca.
LA  - eng
GR  - K23 AR060259/AR/NIAMS NIH HHS/United States
GR  - K23AR060259/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150603
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
SB  - IM
MH  - *Disability Evaluation
MH  - Female
MH  - Humans
MH  - Lupus Erythematosus, Systemic/*diagnosis/*therapy
MH  - Male
MH  - *Severity of Illness Index
PMC - PMC4453215
EDAT- 2015/06/04 06:00
MHDA- 2016/03/26 06:00
PMCR- 2015/06/03
CRDT- 2015/06/04 06:00
PHST- 2015/06/04 06:00 [entrez]
PHST- 2015/06/04 06:00 [pubmed]
PHST- 2016/03/26 06:00 [medline]
PHST- 2015/06/03 00:00 [pmc-release]
AID - 10.1186/s13075-015-0658-6 [pii]
AID - 658 [pii]
AID - 10.1186/s13075-015-0658-6 [doi]
PST - epublish
SO  - Arthritis Res Ther. 2015 Jun 3;17(1):143. doi: 10.1186/s13075-015-0658-6.